- Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1
- Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy.
- Roche/GSK collaboration represents an important step towards a personalised healthcare strategy for certain solid tumour patients.
TUCSON, Ariz., August 18, 2021— Critical Path Institute (C-Path) is pleased to announce that it has selected Kevin Perkins as its new Chief Financial Officer, effective August 9, 2021.Continue reading
In 2020, BIO launched the BIOEquality Agenda, a national effort in collaboration with our partners in the biotechnology sector and BIO members that aims to counteract the systemic inequality, injustice, and unfair treatment of underserved communities.
Today, as part of the BIOEquality Agenda, Dr. Michelle McMurry-Heath, president & CEO of BIO, announced the launch of BIO’s new LinkedIn group, Forum for Diversity in Biotech and STEM to connect BIO members with diverse, talented, and industry-trained individuals. This group will be instrumental in helping our industry invest in the current and next generation of underrepresented scientists and make our entire sector stronger.
On August 10th 2021, the International Society for Cardiovascular Translational Research (ISCTR), the Arizona Bioindustry Association (AZBio), and the University of Arizona James E. Rogers College of Law, Health Law & Policy Program partnered to present an educational webinar on Medical Device Development: Business Planning & Fundraising.Continue reading
TUCSON, Ariz.– The University of Arizona Center for Innovation (UACI) is pleased to announce that QScint Imaging Solutions, LLC. has won the UACI Sponsored Launch Fueled by Concord General Contracting competition.
QScint Imaging Solutions, LLC. manufactures iQID charged-particle digital autoradiography imaging systems for use in radiopharmaceutical drug development, geological studies, and nuclear forensics applications.
TUCSON, AZ, July 27, 2021 – ZelosDx, Inc. announced today that the company is the recipient of a Small Business Innovation Research (SBIR) Phase l Award from the National Science Foundation (NSF) for a grant entitled, “ Phagocytic Cells in Peripheral Blood as a Novel Diagnostic Tool for Brain Health”. The company will receive a one-year grant of up to $255,000 to expand the company’s pioneering biomarker research.Continue reading
Wexford Science & Technology to Open Entrepreneurial Spaces in 850 PBC
Nasdaq’s Board Diversity Rule, which was approved by the SEC on August 6, 2021, is a disclosure standard
designed to encourage a minimum board diversity objective for companies and provide stakeholders with
consistent, comparable disclosures concerning a company’s current board composition. A copy of the approval order can be viewed here.
Immune system alterations could provide a path for future diagnostics and studies of this progressively debilitating neurological disease